Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size

Sep. 27, 2022 11:40 AM ETBellerophon Therapeutics, Inc. (BLPH)By: Anuron Mitra, SA News Editor

Human lungs healthcare and medical abstract background

Silver Place/iStock via Getty Images

  • Bellerophon Therapeutics (NASDAQ:BLPH) on Tuesday said the U.S. FDA had accepted the company's proposal to reduce the study size of its ongoing phase 3 trial of its nitric oxide treatment for fibrotic interstitial lung disease (fILD).
  • Shares of the micro-cap clinical-stage biotherapeutics company rose 23.7% to $1.20 in morning trading.
  • ILD refers to a group of chronic lung diseases in which inflammation and scarring make it hard for the lungs to get enough oxygen.
  • The new study size for the late-stage trial, called REBUILD, was 140 patients, BLPH said in a statement, adding that the change does not impact the trial objective or goals.
  • An independent data monitoring committee also agreed to the new targeted study size.
  • Enrollment in the late-stage trial is now expected to end in Q1 2023, with data readout anticipated in Q3 2023.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.